ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO890

Comorbidity and Multimorbidity Burden in Living Kidney Donors

Session Information

Category: Transplantation

  • 2102 Transplantation: Clinical


  • Lam, Ngan, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada

After donation, living donors may develop one or more risk factors that increase the likelihood of subsequent cardiac and kidney adverse events.


We conducted a cross-sectional, population-based cohort study using linked healthcare databases to study 979 living kidney donors who had donated between 1994 and 2019 in Alberta, Canada. The primary outcome was the presence or history of cardiac and kidney comorbidities, as of March 31, 2020. Cardiac comorbidities included hypertension, diabetes, or major cardiovascular events (myocardial infarction, stroke, or transient ischemic attack). Kidney comorbidities included sustained low eGFR (<45 mL/min/1.73 m2), moderate-severe proteinuria, or kidney stones. Secondary analyses included the presence of other comorbidities, such as cancer, depression, and chronic pain.


The median time since donation was 13 years (IQR 7–19). Of the cardiac comorbidities, hypertension was the most common (31%), followed by diabetes (7%), then major cardiovascular events (5%). Both hypertension and diabetes were present in 5% of donors. For the kidney comorbidities, a history of kidney stones was the most common (12%), while low eGFR (5%) and proteinuria (4%) were uncommon. For the other comorbidities, chronic pain (40%) was most common, followed by depression (36%). Overall, approximately three-quarters of donors had at least 1 comorbidity with the proportion of donors with multimorbidity (≥2 comorbidities) rising with increasing age.


Comorbidity and multimorbidity in the living kidney donor population rises with increasing age. The results of this study may inform long-term follow-up care of donors by identifying those who may benefit most from periodic health reviews.